New serum soluble factors predicting inflammatory and non-inflammatory disability worsening in multiple sclerosis
Year: 2025
Type: article
Study design: Observational Study
Abstract: Introduction Serum neurofilament light chains (sNfL) and glial fibrillary acidic protein (sGFAP) associate respectively with acute inflammation and smoldering disease in relapsing-remitting multiple sclerosis (MS) patients. We explored the proteomic profile associated with the different combinations of low or high levels of sNfL and sGFAP to explore immune mechanisms involved in different MS outcomes. Methods Multicenter cross-sectional study including 253 treatment-naïve PwMS, and 180 healthy controls (HCs). sNfL and sGFAP levels were measured via SIMOA and patients were classified according to their levels into four groups: NLGL (normal sNfL and sGFAP), NHGL (high sNfL/normal sGFAP), NHGH (high sNfL and sGFAP), and NLGH (normal sNfL/high sGFAP). Serum proteomics were measured using the Olink™ 48 Cytokine panel. Results were analyzed by Kruskal-Wallis tests with Dunn’s post hoc analysis and further corrected by the False Discovery Rate analysis. Q-values below 0.05 were considered as significant. Results Compared with HC, patients with low sGFAP concentrations exhibited decreased levels of granulocyte-macrophage colony stimulating factor (GM-CSF), a cytokine inducing innate cell activation q=0.009 for NLGL and q=0.002 for NHGL groups). Conversely, patients with high sGFAP values showed a remarkable decrease of epidermal growth factor (EGF), a cytokine involved in remyelination and axon repair produced by resting astroglia (q<0.0001 for NHGH and NLGH respectively). Additionally, NLGH patients exhibited pronounced decreases in soluble mediators essential for adaptive immune activation, including FLT3LG, TNFSF12, and TNF-α, compared to HC. They also showed broad reductions in chemokines involved in leukocyte recruitment as CCL3, CCL7, and CCL4. The most important decrease was found in CCL2, a chemokine that attracts monocytes and memory T cells to the CNS. NLGH patients showed lower values than HC (q<0.0001), NLGL (q=0.02), NHGL (q=0.02), and NHGH (q=0.03). These findings indicated that NLGH patients experience a reduction of the inflammatory response in the peripheral blood and a decreased immune cell attraction to the central nervous system combined with a lower ability of tissue repair. Discussion We identified new molecules implied in the different pathological mechanisms occurring in patients with MS. These biomarkers could improve patient stratification, outcome prediction, and treatment optimization.
Source: Frontiers in Immunology
Authors: Alexander Rodero-Romero, María Domínguez-Mozo, Enric Monreal, José M. García-Domínguez, Noelia Villarrubia, José Ignacio Fernández-Velasco, Manuel Comabella, Susana Sainz de la Maza, Haydee Goicochea Briceño, Juan Luís Chico-García, María Ángel García-Martínez, Fernando Rodriguez-Jorge, José Luis Veiga-Gonzalez, Raquel Sainz-Amo, María Luisa Martínez Ginés, Xavier Montalban, Jaime Masjuan, Lucienne Costa-Frossard, Roberto Álvarez-Lafuente, Luisa María Villar
Institutions: Instituto de Salud Carlos III, Spanish Multiple Sclerosis Network, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Hospital General Universitario Gregorio Marañón, Universitat Autònoma de Barcelona, Biomedical Research Networking Center on Neurodegenerative Diseases, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Centre d'Esclerosi Múltiple de Catalunya
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Awards: Búsqueda de biomarcadores para la identificación de pacientes con alto riesgo de infecciones graves a lo largo de los tratamientos que inducen la depleción de linfocitos B en la esclerosis múltiple., G4145062930, Mecanismos que median el avance de la discapacidad en la esclerosis múltiple. Identificación de nuevos factores pronósticos y dianas terapéuticas.
OpenAlex ID: W4417024087
